Improvement of CLL-1 CAR-T cells for AML

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K16395
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Teikyo University
• Principal Investigator: Tashiro Haruko 帝京大学, 医学部, 教授 (50433884)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: CAR-T / AML / CLL-1

Outline of Final Research Achievements

CLL-1.CAR/C7R-T cell showed phosphorylation of STAT5 in the absence of any cytokines. Although CLL-1.CAR-T did not survive more than 30 days without cytokines or antigen stimulation, CLL-1.CAR/C7R persisted until day 100. In a serial co-culture assay, CLL-1.CAR/C7R-T cells showed longer anti-tumor activity than CLL-1.CAR-T cells.　In in vivo assay, NSG mice were received CLL-1+ AML cell line, HL60 and then received CLL-1.CAR/C7R-T cells or CLL-1.CAR-T cells. The CLL-1.CAR/C7R-T cells group showed better tumor control.

Free Research Field

血液腫瘍

Academic Significance and Societal Importance of the Research Achievements

CAR-T細胞療法は、今後血液がんのみならず固形がんにも応用されていくことが予想される。より効果的なCAR-Tであるためには、persistencyが重要であり、C7Rを導入することにより、Persistencyが向上することは示せた。